Part I of a series. Dr. Moy previously has recommended ending COVID segregation at Mass.
Since the outbreak of COVID-19, our country has faced unprecedented — and unnecessary — suffering because of misinformation, deceit and censorship foisted on Americans by public health authorities, media, government, private and public institutions, as well as the Catholic Church.
Many countries like the United States have been subjected to unnecessary lockdowns, economic and medical calamities and restrictions on civil and religious liberties. This loss of freedom is currently represented by a growing number of schools and hospitals pushing vaccine mandates with a "medicine" that not only comes with efficacy and safety concerns but that has been developed with morally tainted cell lines derived from aborted babies. What is most reprehensible is that these vaccine mandates are being imposed on employees working in Catholic hospital systems and students who are attending Catholic schools, schools that claim to have a Catholic worldview.
What makes the situation even more shameful is the level of silence from the Vatican and the USCCB towards Catholics who refuse this vaccine on religious grounds, despite the fact that a recent Congregation for the Doctrine of the Faith document clearly states that the vaccine should be voluntary. These vaccine mandates are driven by fear, ignorance and deception. COVID-19 vaccine recommendations are purported to be based on guidelines from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH) and the World Health Organization (WHO) to contain the spread of the virus. Yet COVID-19 vaccines approved by "emergency use authorization" (EUA) represent a medically futile and possibly illegal public health measure.
COVID-19 or SARS-CoV-2 is a ribonucleic acid (RNA) respiratory virus that contains four structural viral proteins or antigens: (1) E or envelope antigen; (2) N-protein or nucleocapsid antigen; (3) M-protein or membrane antigen; and (4) S-protein or spike protein (everyone by now has seen pictures of the spikes on the virus).
There are two traditional vaccine approaches to protecting against infections: (1) an attenuated live vaccine in which the original live virus is weakened but mediates immune protection with a less virulent virus; and (2) a killed whole-virus vaccine.
An attenuated live vaccine would be nasally administered, mimicking the transmission of the COVID-19 virus, while a killed whole-virus vaccine is administered as an intramuscular injection. An attenuated live vaccine produces three important mechanisms of action, namely (1) respiratory mucosal immunity, which facilitates a reduction in viral transmission and respiratory injury; (2) systemic humoral immunity, which elicits an immediate but transient systemic antibody response; and (3) systemic T-cell immunity, which provides more long-term immunity that prevents reinfection.
For example, children who recovered from chickenpox prior to the availability of a vaccine acquired T-cell immunity. This T-cell immunity prevented reinfection.
Individuals who recover from COVID-19 likely not only possess all three forms of immunity, but they benefit from redundant immunity because of exposure to all four viral antigens. In other words, natural immunity likely provides the most effective firewall against viral transmission and reinfection. An attenuated live vaccine would provide an effective, single-dose and rapid immune protection that includes respiratory mucosal immunity. However, a downside of an attenuated live vaccine is the risk that the weakened virus could revert to the original state.
Since the Wuhan strain emerged in late 2019, hundreds of new strains or variants have emerged around the world (e.g., in the United Kingdom, South Africa, Brazil, India and Peru). Some of these variants have greater transmissibility than the original Wuhan strain but do not necessarily produce greater mortality. COVID-19 has many variants because RNA viruses are very unstable and rapidly mutate. Many mutations are clinically irrelevant, while other mutations can pose unique biological features that make variants more resistant to antiviral therapies.
I and colleagues compared the genetic sequence of these variants and observed that the major genetic differences can be attributed to genetic mutations in the spike protein.
The spike protein is prone to mutation because it is under pressure to adapt in response to its interaction with the angiotensin-converting enzyme-2 (ACE-2) receptor where the infection initiates. In contrast, there is relatively more genetic stability in the non-spike viral antigens. As a result, those that achieve natural immunity are better positioned to resist reinfection from variants because of redundant respiratory mucosal, T-cell and humoral immunity to all COVID-19 viral antigens.
Despite what our public health authorities assert, the efficacy of Operation Warp Speed vaccines is inferior to that of natural immunity. Operation Warp Speed supported eight vaccine candidates from pharmaceutical companies in a rush to deliver an experimental vaccine issued under the EUA. All eight utilized a subunit vaccine approach, a non-traditional vaccine approach for respiratory viral infections in which a fragment of the virus (in this case the spike protein) is administered to elicit a neutralizing antibody to the spike protein. Neutralizing antibodies to the spike protein prevent the virus from binding to the ACE-2 receptor and, thus, prevent the infection.
Six of the vaccine candidates — including the offerings of Moderna, Pfizer and Johnson & Johnson — rely on unprecedented gene therapies. Operation Warp Speed chose only subunit approaches because they were the fastest route to large-scale manufacturing using off-the-shelf technologies, thereby enabling these vaccines to quickly enter clinical trials.
Unfortunately, the Department of Health and Human Services did not support traditional attenuated live vaccine development because many in leadership believed that the development process would take too long. This decision proved shortsighted and remains a major reason why we still do not have to this day an adequate biodefense against novel coronaviruses (whether natural or manmade).
The public is largely unaware that this is not the first time subunit vaccine approaches were attempted to combat novel coronaviruses. These same vaccine approaches were unsuccessful in developing an approved vaccine after the outbreak of SARS-CoV-1 in 2002 and MERS in 2012. Subunit vaccines typically elicit weak immune responses and require booster injections. Subunit vaccines are injected into muscle tissue, which bypasses the ability to elicit a respiratory mucosal immunity. Moreover, subunit vaccines that only express the spike protein are vulnerable for two reasons. First, they do not provide redundant immune protection because they stimulate the immune system with only one viral antigen. Second, vaccine effectiveness relies on the stability of the spike protein, its resistance to significant mutations over time.
However, as noted, RNA viruses are very unstable, and it is impractical and medically futile to protect a global population with a subunit vaccine when the spike protein can change. We are presently witnessing how current vaccines based on the Wuhan spike protein sequence are less effective against the South African and Indian (Delta) variant because the spike protein has significantly mutated. In fact, subunit vaccines could theoretically increase the risk of accelerating variant formation by increasing the biological pressure on the virus to create new variants that will be resistant to the vaccine.
As of early May, there were nearly 10,000 cases of reported breakthrough cases in vaccinated individuals, and the likelihood exists that there will be new breakthrough cases in the months ahead as new variants emerge. Additionally, the CDC is not even keeping track of all breakthrough cases. In Israel, which has the highest vaccination rate using the Pfizer mRNA vaccine, most new cases are caused by the Delta variant.